Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
Rhea-AI Summary
Vivani Medical (NASDAQ: VANI) announced it will present at the Emerging Growth Conference on July 15, 2026. CEO Adam Mendelsohn, Ph.D., will provide a company update in an interactive session scheduled for 4:10 p.m. Eastern Time, with live Q&A and an archived webcast available afterward.
Positive
- None.
Negative
- None.
News Market Reaction – VANI
In the Jul 15 session, VANI gained 0.71%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 07 | Collaboration agreement | Positive | +3.9% | Novo Nordisk agreement to evaluate NPM-139 semaglutide implant for weight management. |
| Jul 02 | Subsidiary merger deal | Positive | +2.4% | Cortigent–ClearOne merger with Vivani receiving 12,500,000 ClearOne shares. |
| Jul 02 | Subsidiary merger deal | Positive | +2.4% | ClearOne merger announcement confirming financing plans of $10–$15 million. |
| Jun 26 | Board change announcement | Positive | +5.3% | Appointment of August J. Moretti to board, including Audit Committee chair role. |
| Jun 25 | Phase 1 trial approval | Positive | -6.6% | Regulatory approval to initiate SLIM-1 Phase 1 trial of NPM-139 semaglutide implant. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news for Vivani has typically seen share-price moves align with positive catalysts, with one notable divergence on a Phase 1 trial approval.
Key Terms
glp-1 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALAMEDA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, biopharmaceutical company developing novel, miniature, GLP-1 drug implants with once- or twice-yearly administration, today announced that it will present at the Emerging Growth Conference on July 15, 2026.
Vivani invites individual and institutional investors as well as advisors and analysts to attend its interactive presentation at the Emerging Growth Conference. Vivani CEO Adam Mendelsohn, Ph.D., will deliver a company update and may subsequently open the floor to questions. Please submit questions in advance to Questions@EmergingGrowth.com.
Vivani will be presenting at 4:10 p.m. Eastern Time.
Please register at the following link to attend the conference and receive any updates released in follow up to the Vivani presentation: https://goto.webcasts.com/starthere.jsp?ei=1764180&tp_key=8f1191cdb2&sti=vani
An archived webcast will be made available after the conference on EmergingGrowth.com and on the Emerging Growth YouTube channel.
About Vivani Medical, Inc.
Leveraging its proprietary NanoPortal™ platform, Vivani develops miniature, biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed for once- or twice-yearly administration to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately
Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that are used in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential thereof, the planned development thereof, and its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays; and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission including the factors described in Vivani’s most recent Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026, as updated by future filings with the SEC. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.
Company Contact:
Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462
Investor and Media Relations Contact:
Jami Taylor
Investor and Media Relations Advisor
investors@vivani.com
(415) 506-8462
